COVID Immune
COVID immune draws upon four existing longitudinal LifeCourse population cohorts: VITALITY, MIS BAIR, HealthNuts and SchoolNuts.
Bringing these cohorts together creates a powerful and rich data resource spanning from ages 1 to 24 years. COVID Immune looks at pre-COVID immune phenotypes and biomarkers and whether they predict susceptibility to and severity of SARS-CoV-2 infection. This study also seeks to understand the clinical features, natural history and long term impacts of SARS-CoV-2 infection on immune phenotypes and other biomarkers; and the psychosocial impacts of SARS-CoV-2 and its management.
COVID-19 specific data collection occurred in 2020 during the height of the COVID-19 pandemic, with a one year follow-up being undertaken in 2021.
Year | 2020 | 2020 | 2021-Ongoing | 2021-Ongoing |
---|---|---|---|---|
Wave | Baseline | Baseline: Clinical | 12 month Follow-up | 12 month Follow-up: Clinical |
Age | 1-14 years | 15-24 years | 2-15 years | 16-25 years |
N | in progress | in progress | ||
RELEVANT LIFECOURSE DOMAINS | Allergies | Allergies | ||
Biosamples | ||||
Demographics | ||||
Education and childcare | ||||
Environmental exposures | ||||
Family environment | ||||
Health services | ||||
Medications and supplements | Medications and supplements | |||
Mental health and behaviour problems | ||||
Methodology | Methodology | |||
Other health information | ||||
Peer relationships | ||||
Psychosocial wellbeing | ||||
Puberty | Puberty | |||
Respiratory health | Respiratory health | |||
Romantic relationships | ||||
Screen and technology use | Screen and technology use | |||
Substance use | Substance use |
Study Summary | |
---|---|
Study name | COVID Immune: Predictors of infection and clinical severity with SARS-CoV-2 in extant longitudinal LifeCourse population cohorts of children/young adults and their household/family contacts |
Study abbreviation | COVID Immune |
Current principal investigator/s |
David Burgner Kirsten Perrett |
Current project manager |
Megan Mathers |
Primary Institution/s |
Murdoch Children’s Research Institute - MCRI
|
Major funding source/s |
Rio Tinto Department of Health and Human Services Victor Chiodo Foundation Morgan Stanley |
Study focus |
To investigate predictors of infection and clinical severity with SARS-CoV-2 in extant longitudinal LifeCourse population cohorts of children aged 1 to 24 years and their household |
Sampling frame |
Children/young adults aged 1 to 24 years from each of 4 established cohorts with existing pre-pandemic immune biospecimens (including PBMCs and/or plasma). |
Primary study type | Consortium / Collaboration |
Primary participant (at recruitment) | Index child |
Year commenced |
2020 |
Is this study ongoing? | Yes - the study is ongoing |
Ongoing recruitment? | No |
Sample size (N) |
1172 participants recruited from four pre-existing cohorts |
Survey data available? | Yes |
Imaging data available? | No |
Linkage to administrative dataset/s? | No, no consent to link to administrative dataset(s) obtained |
Biosamples available? | Yes |
Are data available to others outside study team, with appropriate safeguards and structures in line with the cohort’s ethics and governance processes? | Yes |
Are there any costs associated with data/sample access for approved requests? | There are usually no costs associated with access |
Broadest type of participant consent available |
Unspecified consent (can be used for any future ethically approved research) |
Study Contacts | |
---|---|
Principal investigator/s |
David Burgner Kirsten Perrett |
Project manager |
Megan Mathers |
Study Contact |
Ph: (03) 9936 6029 |